Dopamine transporter: Involvement in selective dopaminergic neurotoxicity and degeneration

Journal of Neural Transmission

Volumn 111, Issue 10-11, 2004, Pages 1267-1286

  Storch, A ^a,c   Ludolph, A C ^a   Schwarz, J ^b  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Dopamine transporter; Dopaminergic degeneration; Neurotoxicity; Parkinson's disease

Indexed keywords

1 METHYL 4 PYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BETA CARBOLINE DERIVATIVE; DOPAMINE; DOPAMINE TRANSPORTER; HETEROCYCLIC COMPOUND; ISOQUINOLINE DERIVATIVE; MITOCHONDRIAL ENZYME; NEUROTRANSMITTER; PYRIDINIUM DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TOXIN; UNCLASSIFIED DRUG;

CHLORIDE TRANSPORT; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ENZYME INHIBITION; GENETIC POLYMORPHISM; HUMAN; HYPOTHALAMUS; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SODIUM TRANSPORT; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

ANIMALS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NEUROTOXICITY SYNDROMES; PARKINSON DISEASE;

EID: 7944227203     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-004-0203-2     Document Type: Review

References (120)

1. 2 in chromaffin cells. Eur J Pharmacol 293: 55-64
2. Amara SG, Kuhar MJ (1993) Neurotransmitter transporters: recent progress. Annu Rev Neurosci 16: 73-93
3. Andrew R, Watson DG, Best SA, Midgley JM, Wenlong H, Petty RK (1993) The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem Res 18: 1175-1177
4. Augood SJ, Westmore K, McKenna PJ, Emson PC (1993) Co-expression of dopamine transporter mRNA and tyrosine hydroxylase mRNA in ventral mesencephalic neurones. Brain Res Mol Brain Res 20: 328-334
5. Bezard E, Gross CE, Fournier MC, Dovero S, Bloch B, Jaber M (1999) Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp Neurol 155: 268-273
6. Bloomquist J, King E, Wright A, Mytilineou C, Kimura K, Castagnoli K, Castagnoli N Jr (1994) 1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies. J Pharmacol Exp Ther 270: 822-830
7. Breese GR, Traylor TD (1970) Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons. J Pharmacol Exp Ther 174: 413-420
8. Bringmann G, God R, Feineis D, Wesemann W, Riederer P, Rausch WD, Reichmann H, Sontag KH (1995) The TaClo concept: 1-trichloromethyl-l,2,3,4- tetrahydro-beta-carboline (TaClo), a new toxin for dopaminergic neurons. J Neural Transm [Suppl] 46: 235-244
9. Bringmann G, Bruckner R, Mossner R, Feineis D, Heils A, Lesch KP (2000) Effect of 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo) on human serotonergic cells. Neurochem Res 25: 837-843
10. Bryan-Lluka LJ, Siebert GA, Pond SM (1999) Potencies of haloperidol metabolites as inhibitors of the human noradrenaline, dopamine and serotonin transporters in transfected COS-7 cells. Naunyn Schmiedebergs Arch Pharmacol 360: 109-115
11. Buck KJ, Amara SG (1994) Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium. Proc Natl Acad Sci USA 91: 12584-12588
12. Cerruti C, Drian MJ, Kamenka JM, Privat A (1993a) Protection by BTCP of cultured dopaminergic neurons exposed to neurotoxins. Brain Res 617: 138-142
13. Cerruti C, Walther DM, Kuhar MJ, Uhl GR (1993b) Dopamine transporter mRNA expression is intense in rat midbrain neurons and modest outside midbrain. Brain Res Mol Brain Res 18: 181-186
14. Chiba K, Trevor A, Castagnoli N Jr (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120: 574-578
15. +, a metabolite of MPTP, by brain synaptosomes. Biochem Biophys Res Commun 128: 1228-1232
16. Ciliax BJ, Drash GW, Staley JK, Haber S, Mobley CJ, Miller GW, Mufson EJ, Mash DC, Levey AI (1999) Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol 409: 38-56
17. + in PC12 cells: insights into potential neurotoxicants in Parkinson's disease. J Neurochem 62: 1503-1510
18. + as environmental neurotoxins. In: Storch A, Collins MA (eds) Neurotoxic factors in Parkinson's disease and related disorders. Kluwer Academic Plenum Press, New York, pp 115-130
19. Collins MA, Neafsey EJ, Cheng BY, Hurley-Gius K, Ung-Chhun NA, Pronger DA, Christiansen MA, Hurley-Gius D (1986) Endogenous analogs of MPTP: indolamine-derived tetrahydro-β-carbolines as potential causative factors in Parkinson's diseases. Adv Neurol 45: 179-182
20. + in mesencephalic cultures. Soc Neurosci Abstr 21: 1259
21. Collins MA, Neafsey EJ, Matsubara K (1996) β-Carbolines: metabolism and neurotoxicity. Biogen Amines 12: 171-180
22. Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, Staal R, Tieu K, Schmitz Y, Yuan CA, Rocha M, Jackson-Lewis V, Hersch S, Sulzer D, Przedborski S, Burke R, Hen R (2002) Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA 99: 14524-14529
23. Decker DE, Althaus JS, Buxser SE, VonVoigtlander PF, Ruppel PL (1993) Competitive irreversible inhibition of dopamine uptake by 6-hydroxydopamine. Res Commun Chem Pathol Pharmacol 79: 195-208
24. +) cytotoxicity. Biochem Biophys Res Commun 137: 303-309
25. 3H]mazindol autoradiography. J Comp Neurol 304: 419-434
26. Donovan DM, Miner LL, Perry MP, Revay RS, Sharpe LG, Przedborski S, Kostic V, Philpot RM, Kirstein CL, Rothman RB, Schindler CW, Uhl GR (1999) Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. Brain Res Mol Brain Res 73: 37-49
27. Drucker G, Raikoff K, Neafsey EJ, Collins MA (1990) Dopamine uptake inhibitory capacities of beta-carboline and 3,4-dihydro-beta-carboline analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation products. Brain Res 509: 125-133
28. Forno LS, Langston JW, DeLanney LE, Irwin I, Ricaurte GA (1986) Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 20: 449-455
29. Gainetdinov RR, Fumagalli F, Jones SR, Caron MG (1997) Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 69: 1322-1325
30. Gerlach M, Xiao AY, Heim C, Lan J, God R, Feineis D, Bringmann G, Riederer P, Sontag KH (1998) 1-Trichloromethyl-1,2,3,4-tetrahydro-beta-carboline increases extracellular serotonin and stimulates hydroxyl radical production in rats. Neurosci Lett 257: 17-20
31. German DC, Manaye K, Smith WK, Woodward DJ, Saper CB (1989) Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann Neurol 26: 507-514
32. Giros B, Caron MG (1993) Molecular characterization of the dopamine transporter. Trends Pharmacol Sci 14: 43-49
33. Giros B, el Mestikawy S, Godinot N, Zheng K, Han H, Yang-Feng T, Caron MG (1992) Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol 42: 383-390
34. Goto K, Mochizuki H, Hattori T, Nakamura N, Mizuno Y (1997) Neurotoxic effects of papaverine, tetrahydropapaverine and dimethoxyphenylethylamine on dopaminergic neurons in ventral mesencephalic-striatal co-culture. Brain Res 754: 260-268
35. Heikkila R, Cohen G, Dembiec D (1971) Tetrahydroisoquinoline alkaloids: uptake by rat brain homogenates and inhibition of catecholamine uptake. J Pharmacol Exp Ther 179: 250-258
36. Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG, Lee KS, Linnoila M, Weinberger DR (2000) Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22: 133-139
37. Hersch SM, Yi H, Heilman CJ, Edwards RH, Levey AI (1997) Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. J Comp Neurol 388: 211-227
38. Hirata Y, Minami M, Naoi M, Nagatsu T (1990) Studies on the uptake of N-methylisoquinolinium ion into rat striatal slices using high-performance liquid chromatography with fluorimetric detection. J Chromatogr 503: 189-195
39. Hitri A, Hurd YL, Wyatt RJ, Deutsch SI (1994) Molecular, functional and biochemical characteristics of the dopamine transporter: regional differences and clinical relevance. Clin Neuropharmacol 17: 1-22
40. Huff RA, Vaughan RA, Kuhar MJ, Uhl GR (1997) Phorbol esters increase dopamine transporter phosphorylation and decrease transport Vmax. J Neurochem 68: 225-232
41. Hurd YL, Pristupa ZB, Herman MM, Niznik HB, Kleinman JE (1994) The dopamine transporter and dopamine D2 receptor messenger RNAs are differentially expressed in limbic- and motor-related subpopulations of human mesencephalic neurons. Neuroscience 63: 357-362
42. 3H]GBR-12935 binding to the dopamine transporter is decreased in the caudate nucleus in Parkinson's disease. J Neurochem 49: 617-621
43. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82: 2173-2177
44. Jonsson G, Sachs C (1971) Uptake and accumulation of 3 H-6-hydroxydopamine in adrenergic nerves. Eur J Pharmacol 16: 55-62
45. Kawai H, Makino Y, Hirobe M, Ohta S (1998) Novel endogenous 1,2,3,4-tetrahydroisoquinoline derivatives: uptake by dopamine transporter and activity to induce parkinsonism. J Neurochem 70: 745-751
46. Kilty JE, Lorang D, Amara SG (1991) Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science 254: 578-579
47. Kimura M, Matsushita S, Arai H, Takeda A, Higuchi S (2001) No evidence of association between a dopamine transporter gene polymorphism (1215A/G) and Parkinson's disease. Ann Neurol 49: 276-277
48. +: uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA. Ann Neurol 32: 109-111
49. Kitayama S, Shimada S, Xu H, Markham L, Donovan DM, Uhl GR (1992b) Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci USA 89: 7782-7785
50. + transport. Synapse 15: 58-62
51. Kitayama S, Dohi T, Uhl GR (1994) Phorbol esters alter functions of the expressed dopamine transporter. Eur J Pharmacol 268: 115-119
52. Kitayama S, Morita K, Dohi T (1996a) Uptake and release of dopamine through the rat dopamine transporter expressed in Xenopus laevis oocyte: evaluation by voltammetric measurement of intracellular dopamine concentration. Neurosci Lett 211: 132-134
53. + but not dopamine through the rat dopamine transporter. Eur J Pharmacol 309: 107-109
54. Kitayama S, Morita K, Dohi T, Wang JB, Davis SC, Uhl GR (1996c) Dissection of dopamine and cocaine binding sites on the rat dopamine transporter expressed in COS cells. Ann NY Acad Sci 801: 388-393
55. + toxicity and plasma membrane dopamine transporter: study using cell lines expressing the wild-type and mutant rat dopamine transporters. Biochim Biophys Acta 1404: 305-313
56. Kostrzewa RM, Jacobowitz DM (1974) Pharmacological actions of 6-hydroxydopamine. Pharmacol Rev 26: 199-288
57. Krueger BK (1990) Kinetics and block of dopamine uptake in synaptosomes from rat caudate nucleus. J Neurochem 55: 260-267
58. Kutty RK, Santostasi G, Horng J, Krishna G (1991) MPTP-induced ATP depletion and cell death in neuroblastoma X glioma hybrid NG 108-15 cells: protection by glucose and sensitization by tetraphenylborate. Toxicol Appl Pharmacol 107: 377-388
59. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980
60. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-melhyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46: 598-605
61. Le Couteur DG, Leighton PW, McCann SJ, Pond S (1997) Association of a polymorphism in the dopamine-transporter gene with Parkinson's disease. Mov Disord 12: 760-763
62. Lee SH, Chang MY, Lee KH, Park BS, Lee YS, Chin HR (2000) Importance of valine at position 152 for the substrate transport and 2beta-carbomethoxy-3beta- (4-fluorophenyl)tropane binding of dopamine transporter. Mol Pharmacol 57: 883-889
63. Lee FJ, Liu F, Pristupa ZB, Niznik HB (2001a) Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. Faseb J 15: 916-926
64. Lee M, Hyun D, Halliwell B, Jenner P (2001b) Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J Neurochem 76: 998-1009
65. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, Jones T, Marsden CD, Frackowiak RS (1990) The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 47: 1290-1298
66. + toxicity in vitro. Neuroreport 13: 1279-1283
67. Leighton PW, Le Couteur DG, Pang CC, McCann SJ, Chan D, Law LK, Kay R, Pond SM, Woo J (1997) The dopamine transporter gene and Parkinson's disease in a Chinese population. Neurology 49: 1577-1579
68. Lin CN, Liu HC, Tsai SJ, Liu TY, Hong CJ (2002) Association study for Parkinson's disease and a dopamine transporter gene polymorphism (1215A/G). Eur Neurol 48: 207-209
69. Lin JJ, Yueh KC, Chang DC, Chang CY, Yeh YH, Lin SZ (2003) The homozygote 10-copy genotype of variable number tandem repeat dopamine transporter gene may confer protection against Parkinson's disease for male, but not to female patients. J Neurol Sci 209: 87-92
70. Lin Z, Uhl GR (2002) Dopamine transporter mutants with cocaine resistance and normal dopamine uptake provide targets for cocaine antagonism. Mol Pharmacol 61: 885-891
71. Lin Z, Uhl GR (2003) Human dopamine transporter gene variation: effects of protein coding variants V55A and V382A on expression and uptake activities. Pharmacogenomics J 3: 159-168
72. Lin Z, Wang W, Kopajtic T, Revay RS, Uhl GR (1999) Dopamine transporter: transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition. Mol Pharmacol 56: 434-447
73. Lin Z, Itokawa M, Uhl GR (2000a) Dopamine transporter proline mutations influence dopamine uptake, cocaine analog recognition, and expression. Faseb J 14: 715-728
74. Lin Z, Wang W, Uhl GR (2000b) Dopamine transporter tryptophan mutants highlight candidate dopamine- and cocaine-selective domains. Mol Pharmacol 58: 1581-1592
75. Lorang D, Amara SG, Simerly RB (1994) Cell-type-specific expression of catecholamine transporters in the rat brain. J Neurosci 14: 4903-4914
76. Maruyama W, Abe T, Tohgi H, Dosiert P, Naoi M (1996) A dopaminergic neurotoxin, (R)-N-methylsalsolinol, increases in Parkinsonian cerebrospinal fluid. Ann Neurol 40: 119-122
77. Maruyama W, Naoi M, Kasamatsu T, Hashizume Y, Takahashi T, Kohda K, Dostert P (1997) An endogenous dopaminergic neurotoxin, N-methyl-(R)-salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells. J Neurochem 69: 322-329
78. Matsubara K, Gonda T, Sawada H, Uezono T, Kobayashi Y, Kawamura T, Ohtaki K, Kimura K, Akaike A (1998a) Endogenously occurring beta-carboline induces parkinsonism in non-primate animals: a possible causative protoxin in idiopathic Parkinson's disease. J Neurochem 70: 727-735
79. Matsubara K, Senda T, Uezono T, Fukushima S, Ohta S, Igarashi K, Naoi M, Yamashita Y, Ohtaki K, Hayase N, Akutsu S, Kimura K (1998b) Structural significance of azaheterocyclic amines related to Parkinson's disease for dopamine transporter. Eur J Pharmacol 348: 77-84
80. Mayer RA, Kindt MV, Heikkila RE (1986) Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylethylamine transport. J Neurochem 47: 1073-1079
81. McElvain JS, Schenk JO (1992) A multisubstrate mechanism of striatal dopamine uptake and its inhibition by cocaine. Biochem Pharmacol 43: 2189-2199
82. McNaught KS, Thull U, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, Marsden CD (1996a) Toxicity to PC12 cells of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Neurosci Lett 206: 37-40
83. 3H]dopamine uptake into striatal synaptosomes by isoquinoline derivatives structurally related to 1-meihyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochem Pharmacol 52: 29-34
84. McNaught KS, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, Marsden CD (1998) Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease. Biochem Pharmacol 56: 921-933
85. Melchior C, Collins MA (1982) The route and significance of endogenous synthesis of alkaloids in animals. Crit Rev Toxicol 9: 313-356
86. Mercier G, Turpin JC, Lucotte G (1999) Variable number tandem repeat dopamine transporter gene polymorphism and Parkinson's disease: no association found. J Neurol 246: 45-47
87. Michel PP, Dandapani BK, Sanchez-Ramos J, Efange S, Pressman BC, Hefti F (1989) Toxic effects of potential environmental neurotoxins related to 1-methyl-4-phenylpyridinium on cultured rat dopaminergic neurons. J Pharmacol Exp Ther 248: 842-850
88. Michel PP, Dandapani BK, Knusel B, Sanchez-Ramos J, Hefti F (1990) Toxicity of 1-methyl-4-phenylpyridinium for rat dopaminergic neurons in culture: selectivity and irreversibility. J Neurochem 54: 1102-1109
89. Miller GW, Staley JK, Heilman CJ, Perez JT, Mash DC, Rye DB, Levey AI (1997) Immuno-chemical analysis of dopamine transporter protein in Parkinson's disease. Ann Neurol 41: 530-539
90. Mitsuhata C, Kitayama S, Morita K, Vandenbergh D, Uhl GR, Dohi T (1998) Tyrosine-533 of rat dopamine transporter: involvement in interactions with 1-methyl-4-phenylpyridinium and cocaine. Brain Res Mol Brain Res 56: 84-88
91. Morino H, Kawarai T, Izumi Y, Kazuta T, Oda M, Komure O, Udaka F, Kameyama M, Nakamura S, Kawakami H (2000) A single nucleotide polymorphism of dopamine transporter gene is associated with Parkinson's disease. Ann Neurol 47: 528-531
92. Naoi M, Maruyama W, Nakao N, Ibi T, Sahashi K, Benedetti MS (1998) (R)salsolinol N-methyltransferase activity increases in parkinsonian lymphocytes, Ann Neurol 43: 212-216
93. Nirenberg MJ, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM (1996) The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci 16: 436-447
94. Nishimura M, Kaji R, Ohta M, Mizuta I, Kuno S (2002) Association between dopamine transporter gene polymorphism and susceptibility to Parkinson's disease in Japan. Mov Disord 17: 831-832
95. Pakkenberg B, Moller A, Gundersen HJ, Mouritzen Dam A, Pakkenberg H (1991) The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 54: 30-33
96. Pifl C, Giros B, Caron MG (1993) Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J Neurosci 13: 4246-4253
97. Pifl C, Hornykiewicz O, Giros B, Caron MG (1996) Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: studies comparing the cloned human noradrenaline and human dopamine transporter. J Pharmacol Exp Ther 277: 1437-1443
98. Plante-Bordeneuve V, Taussig D, Thomas F, Said G, Wood NW, Marsden CD, Harding AE (1997) Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: evidence for association of a DRD2 allele. Neurology 48: 1589-1593
99. Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, Almer G (2000) The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 16: 135-142
100. Ramsay RR, Singer TP (1986) Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine, by mitochondria. J Biol Chem 261: 7585-7587
101. Ricaurte GA, Langston JW, DeLanney LE, Irwin I, Brooks JD (1985) Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum. Neurosci Lett 59: 259-264
102. Russ H, Staust K, Martel F, Gliese M, Schomig E (1996) The extraneuronal transporter for monoamine transmitters exists in cells derived from human central nervous system glia. Eur J Neurosci 8: 1256-1264
103. Sano A, Kondoh K, Kakimoto Y, Kondo I (1993) A 40-nucleotide repeat polymorphism in the human dopamine transporter gene. Hum Genet 91: 405-406
104. Shimada S, Kitayama S, Walther D, Uhl G (1992) Dopamine transporter mRNA: dense expression in ventral midbrain neurons. Brain Res Mol Brain Res 13: 359-362
105. Sidhu A, Wersinger C, Vernier P (2004) alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. FEBS Lett 565: 1-5
106. Staley JK, Boja JW, Carroll FI, Seltzman HH, Wyrick CD, Lewin AH, Abraham P, Mash DC (1995) Mapping dopamine transporters in the human brain with novel selective cocaine analog [125I]RTI-121. Synapse 21: 364-372
107. +) via impairment of energy metabolism. Neurochem Int 35: 393-403
108. Storch A, Kaftan A, Burkhardt K, Schwarz J (2000a) 1-Methyl-6,7- dihydroxy-1,2,3,4-tetrahydroisoquinoline (salsolinol) is toxic to dopaminergic neuroblastoma SH-SY5Y cells via impairment of cellular energy metabolism. Brain Res 855: 67-75
109. Storch A, Kaftan A, Burkhardt K, Schwarz J (2000b) 6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism. J Neural Transm 107: 281-293
110. Storch A, Ott S, Hwang YI, Ortmann R, Hein A, Frenzel S, Matsubara K, Ohta S, Wolf HU, Schwarz J (2002) Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson's disease: studies using heterologous expression systems of the dopamine transporter. Biochem Pharmacol 63: 909-920
111. Storch A, Hwang YI, Gearhart DA, Beach JW, Collins MA, Schwarz J (2004) Selective dopaminergic toxicity of b-carboline derivatives related to Parkinson's disease. J Neurochem 89(3): 685-694
112. Takahashi T, Deng Y, Maruyama W, Dostert P, Kawai M, Naoi M (1994) Uptake of a neurotoxin-candidate, (R)-1,2-dimethyl-6,7-dihydroxy-1,2,3,4- tetrahydroisoquinoline into human dopaminergic neuroblastoma SH-SY5Y cells by dopamine transport system. J Neural Transm [Gen Sect] 98: 107-118
113. Takahashi T, Maruyama W, Deng Y, Dostert P, Nakahara D, Niwa T, Ohta S, Naoi M (1997) Cytotoxicity of endogenous isoquinolines to human dopaminergic neuroblasloma SH-SY5Y cells. J Neural Transm 104: 59-66
114. Tatsch K, Schwarz J, Mozley PD, Linke R, Pogarell O, Oertel WH, Fieber RS, Hahn K, Kung HF (1997) Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography. Eur J Nucl Med 24: 415-421
115. Uhl GR, Lin Z (2003) The top 20 dopamine transporter mutants: structure-function relationships and cocaine actions. Eur J Pharmacol 479: 71-82
116. Uhl GR, Hedreen JC, Price DL (1985) Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology 35: 1215-1218
117. Uhl GR, Walther D, Mash D, Faucheux B, Javoy-Agid F (1994) Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann Neurol 35: 494-498
118. Usdin TB, Mezey E, Chen C, Brownstein MJ, Huffman BJ (1991) Cloning of the cocaine-sensitive bovine dopamine transporter. Proc Natl Acad Sci USA 88: 11168-11171
119. Waring RH, Steventon GB, Sturman SG, Heafield MT, Smith MC, Williams AC (1989) S-methylation in motorneuron disease and Parkinson's disease. Lancet 2: 356-357
120. Waters CM, Peck R, Rossor M, Reynolds GP, Hunt SP (1988) Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea. Neuroscience 25: 419-438